Psychedelic Therapy in Lithuania: Every Legal Route in 2026

If you are looking into psychedelic-assisted treatment in Lithuania — for yourself or for someone close to you — the country in July 2026 offers one route you can act on, and it is private. Esketamine is a registered medicine here, but we could not confirm public coverage; the practical option is a licensed ketamine clinic in Vilnius with published programmes and prices. Psilocybin and MDMA are research-only. This guide covers who qualifies, how to start, what it costs, and what remains unverified; you can begin orienting yourself with our eligibility check.

At a glance

How Lithuania compares across the continent: Europe-wide reimbursement map.

Esketamine in Lithuania: registered medicine, unconfirmed coverage

Spravato has been registered in Lithuania since 18 December 2019 (VVKT medicines register) for treatment-resistant depression, in combination with an SSRI or SNRI, under physician supervision — its arrival was covered by national media at the time (LRT). Reimbursed medicines in Lithuania must appear on the state's compensation lists (LNCP overview), and we could not find esketamine on them — nor any public hospital advertising an esketamine service. Until that changes, the realistic route is self-pay; for the numbers in European context see our cost guide.

Private ketamine at Noos klinika: KIT and KAP

Noos klinika in Vilnius (Kernavės g. 14-50; healthcare institution licence No. 5879) states it is the first clinic in Lithuania and the Baltics to apply KIT and KAP. Two formats are offered, with movement between them:

• KIT — ketamine infusion/injection therapy. A biomedical protocol: a series of three or six carefully administered low-dose intramuscular ketamine sessions without psychotherapy, aimed at direct symptom relief in treatment-resistant depression, anxiety and PTSD. Sessions run up to two hours with psychological and medical supervision, typically twice a week.
• KAP — ketamine-assisted psychotherapy. Longer three-hour sessions, less frequent, with psychotherapy integrated and the dose individualised — the clinic frames it for patients seeking broader therapeutic work, not only symptom relief.

How to start and what it costs. Every patient begins with the intake block — an introductory consultation, a baseline psychiatric assessment with questionnaires, and a treatment-selection decision (€150). The published programmes: KIT-3 (three sessions over two weeks) at €1,350; KIT-6 (six sessions over three to four weeks) at €2,700; single booster sessions at €450 after a completed programme (Noos klinika). Ketamine here is used off-label, which is legal and standard practice — the clinic's physician decides admission after screening. Advance registration is required; the clinic also publishes English-language pages (about). To see what is listed for Lithuania, browse providers in Lithuania.

What we don't know yet

An honest list of the gaps in our verification, as of 30 July 2026:

• Reimbursement status. We could not confirm esketamine on Lithuania's compensated-medicines lists, but we also cannot prove a negative — verify with your territorial health insurance fund (TLK) before assuming self-pay is the only option.
• Public-sector use. Whether any Lithuanian hospital administers esketamine or ketamine for depression outside research is unverified.
• Other private providers. Noos klinika is the only Lithuanian clinic we have verified; others may exist.
• The clinic's claimed efficacy figures. Noos cites 70–80 per cent response rates from the ketamine literature; treat those as trial-population figures, not a personal prediction.

Psilocybin and MDMA: research only

Psilocybin and MDMA remain controlled substances in Lithuania with no medical-access route (Psychedelic Alpha tracker), and our tracked registry data shows no Lithuanian psychedelic trial site. The realistic option is a trial elsewhere in Europe — our trials guide explains how to search. Anyone offering psilocybin or MDMA therapy commercially in Lithuania today is operating illegally.

What to expect in treatment

Whichever route you take, the shape of care is similar and worth picturing in advance. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.

On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate and how you feel; dissociation and a temporary rise in blood pressure are expected and settle as the drug clears. You must not drive for the rest of the day, so arrange a ride home. Induction is typically more frequent at first and then tapers based on measured response, always combined with a continuing oral antidepressant.

A ketamine infusion is usually given intravenously over about 40–60 minutes with the same vital-sign monitoring and a recovery period afterwards; KAP programs wrap the dosing in preparation and integration sessions with a therapist. Where a legal psychedelic-therapy route exists (a compassionate-use programme, a regulated PAT programme or a clinical trial — availability differs by country), dosing days are long and closely supervised — two trained professionals including a physician stay with you — and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up are what make it safe, and psychotherapy or integration is what helps the effect last.

Risks and who should not start

These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:

• Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease, because of the temporary rise in blood pressure.
• A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
• Pregnancy or breastfeeding.
• Substance-use concerns, particularly patterns of compulsive use.

A responsible provider screens for all of these before the first dose. If a clinic is willing to treat you without that assessment, treat it as a warning sign — see our clinic-choice guide. To see who is listed near you, browse providers in Germany.

Frequently asked questions

Is esketamine (Spravato) reimbursed in Lithuania?

Not as far as we could confirm. The medicine has been registered since 2019, but we found no entry on the compensated-medicines lists and no public esketamine service. If coverage matters to your decision, ask your psychiatrist or territorial health insurance fund directly.

What is the difference between KIT and KAP?

KIT is the biological protocol: shorter (up to two hours), more frequent, fixed low-dose sessions without psychotherapy, aimed at rapid symptom relief. KAP wraps individualised dosing in three-hour psychotherapy sessions held less often. The clinic's intake consultation exists to help you choose, and switching between the two is possible.

How much does ketamine treatment cost in Lithuania?

At Noos klinika: €1,350 for a three-session KIT programme or €2,700 for six sessions, each plus a €150 intake block, and €450 for a single booster afterwards. KAP is priced separately — ask the clinic for a written breakdown before starting.

Can I get psilocybin or MDMA therapy in Lithuania?

No. Both are research-only, no Lithuanian trial is in our tracked data, and no legal clinical route exists. Watch the registries or consider trial sites elsewhere in Europe.

Sources

1. Noos klinika: Ketamine infusion/injection therapy (KIT) — programmes, prices, supervision
2. Noos klinika: About the ketamine clinic (English)
3. VVKT — State Medicines Control Agency: Spravato registration record
4. LNCP: Reimbursed medicines in Lithuania — how the system works
5. LRT: Nasal spray against depressive thoughts — Spravato's registration in Lithuania
6. EMA: Spravato (esketamine) EPAR
7. Psychedelic Alpha: Worldwide psychedelic laws tracker
8. ClinicalTrials.gov

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations, prices and coverage rules can change; always verify current requirements with the VVKT, your territorial health insurance fund, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This guide awaits review by a licensed medical professional.